An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.

Purpose: The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM).Procedures: A human anti-ALCAM single chain variable fragment was reformatted to produce a covalent dimer, termed a cys-diabod...

Descripción completa

Detalles Bibliográficos
Publicado en:Molecular Imaging & Biology Vol. 14; no. 3; pp. 336 - 348
Autores principales: McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM, McCabe, Katelyn E, Liu, Bin, Marks, James D, Tomlinson, James S, Wu, Hong, Wu, Anna M
Formato: research Journal Article
Publicado: Springer Nature Jun2012
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Purpose: The purpose of this study was to generate and evaluate a positron emission tomography (PET) radiotracer targeting activated leukocyte cell adhesion molecule (ALCAM).Procedures: A human anti-ALCAM single chain variable fragment was reformatted to produce a covalent dimer, termed a cys-diabody (CysDb). Purified CysDb was characterized by gel electrophoresis and size exclusion chromatography, and immunoreactivity was assessed by flow cytometry and immunofluorescence. Targeting and imaging of ALCAM-positive tumors using (64)Cu-DOTA-CysDb were evaluated in mice bearing human pancreatic adenocarcinoma xenografts (HPAF-II or BxPC-3).Results: CysDb binds specifically to ALCAM-positive cells in vitro with an apparent affinity in the range of 1-3 nM. MicroPET images at 4 h showed specific targeting of positive tumors in vivo, a finding confirmed by biodistribution analysis, with positive/negative tumor ratios of 1.9 ± 0.6 and 2.4 ± 0.6, and positive tumor/blood ratios of 2.5 ± 0.9 and 2.9 ± 0.6 (HPAF-II and BxPC-3, respectively).Conclusions: Successful imaging with (64)Cu-DOTA-CysDb in animal models suggests further investigation of ALCAM as an imaging biomarker is warranted.